Skip to content

Thermic Effect of Feeding in Cystic Fibrosis

Thermic Effect of Feeding in Cystic Fibrosis

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03931252
Enrollment
0
Registered
2019-04-30
Start date
2022-01-31
Completion date
2022-12-31
Last updated
2022-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Brief summary

The investigators propose to assess the contributions of the thermic effect of food intake (TEF), which is the amount of energy expended to digest food, to overall energy expenditure in Cystic Fibrosis (CF).

Detailed description

Total energy expenditure (TEE) is comprised of the following components: resting energy expenditure (REE), thermic effect of food intake (TEF), adaptive thermogenesis (AT). The thermic effect of food is the amount of energy expended to digest food, and can be affected by factors such as protein / fat / carbohydrate contents of meals or the amount of time over which a meal is consumed. The investigators propose to assess the contributions of the thermic effect of food intake (TEF), which is the amount of energy expended to digest food, to overall energy expenditure in CF. Participants will be assigned to either a high fat liquid meal or a high protein liquid meal and assessed for components of energy expenditure in the whole room indirect calorimeter (metabolic chamber); participants will then be crossed over to the alternate liquid meal type, and differences in resting and total energy expenditure and the thermic effect of food will be assessed between the two types of meals.

Interventions

DIETARY_SUPPLEMENTBoost VHC

8 ounce can liquid meal, calories 530kcal, Carbohydrate 46g, Protein 22g, Fat 30g

DIETARY_SUPPLEMENTEnsure High Protein

8 ounce can liquid meal, calories 160kcal, Carbohydrate 13g, Protein 16g, Fat 2g

Sponsors

Virginia Commonwealth University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* confirmed diagnosis of cystic fibrosis by Cystic Fibrosis Foundation-established criteria * being followed at the VCU (Virginia Commonwealth University) Adult Cystic Fibrosis Center * pulmonary and overall health status at baseline as assessed by pulmonary function testing and screening labs (complete blood count, liver enzymes, cholesterol, HgA1c). Criteria for baseline status are established for each individual patient as part of routine CF pulmonary care. * ability to understand the study procedures and to comply with them for the entire length of the study

Exclusion criteria

* experiencing any signs or symptoms consistent with a pulmonary exacerbation (a decline in pulmonary function testing from baseline, recorded as part of routine CF care) * undergoing treatment for a pulmonary exacerbation with a change in antibiotics or steroids from their baseline medications * tobacco users * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Energy Expenditure16 hours after entry into metabolic chamberThe changes in energy expenditure measured in kcal (resting energy expenditure prior to feeding, and thermic effect of food after meal administration) will be recorded in the metabolic chamber.

Secondary

MeasureTime frameDescription
glucose16 hours after entry into metabolic chamberblood glucose (mg/dL) measured with continuous glucose sensor and fasting venous sample at end of study visit
insulin16 hours after entry into metabolic chamberfasting insulin level (mIU/mL) measured at end of overnight visit
Leptin16 hours after entry into metabolic chamberfasting leptin level (ng/mL) measured at end of overnight visit
Ghrelin16 hours after entry into metabolic chamberfasting grehlin levels (pg/mL) measured at end of overnight visit

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026